Conjugates comprising an antigen and a carrier molecule

Patent metadata

Field	Value
Publication number	US-9493517-B2
Application number	US-201213670727-A
Country	US
Kind code	B2
Filing date	Nov 7, 2012
Priority date	Nov 7, 2011
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a spr0096 antigen and a spr2021 antigen. spr0096 and spr2021 are Streptococcus pneumoniae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.

First claim

What is claimed is:

1. A conjugate comprising an antigen covalently linked to a carrier molecule, wherein the carrier molecule comprises a spr0096 antigen covalently linked to a spr2021 antigen and the antigen is a bacterial capsular saccharide.

2. The conjugate of claim 1 , wherein the carrier molecule comprises the spr0096 antigen and the spr2021 antigen as a single polypeptide chain.

3. The conjugate of claim 2 , wherein the spr0096 antigen comprises an amino acid sequence having 50% or more identity to SEQ ID NO: 1 or SEQ ID NO: 2.

4. The conjugate of claim 2 , wherein the spr2021 antigen comprises an amino acid sequence having 50% or more identity to SEQ ID NO: 3.

5. The conjugate of claim 3 , wherein the spr2021 antigen comprises an amino acid sequence having 50% or more identity to SEQ ID NO: 3.

6. The conjugate of claim 2 , wherein the polypeptide chain is of the formula NH 2 -A-{-X-L-} n -B—COOH, wherein: A is an optional N-terminal amino acid sequence; B is an optional C-terminal amino acid sequence; n is an integer of 2 or more such that there is at least an X 1 and an X 2 ; each X is an amino acid sequence of an spr0096 antigen or an spr2021 antigen, wherein at least one X is an spr0096 antigen and at least one X is an spr2021 antigen; and L is an optional linker amino acid sequence.

7. The conjugate of claim 6 , wherein n is 2.

8. The conjugate of claim 7 , wherein the X 1 is an spr0096 antigen and the X 2 is an spr2021 antigen.

9. The conjugate of claim 8 , wherein the spr0096 antigen comprises an amino acid sequence having 50% or more identity to SEQ ID NO: 1 or SEQ ID NO: 2, and the spr2021 antigen comprises an amino acid sequence having 50% or more identity to SEQ ID NO: 3.

10. The conjugate of claim 1 , wherein the bacterial capsular saccharide is a capsular saccharide from N. meningitidis or a capsular saccharide from S. pneumoniae.

11. The conjugate of claim 1 , wherein the bacterial capsular saccharide is a capsular saccharide from N. meningitidis serogroup A, C, W135 or Y.

12. A pharmaceutical composition comprising a conjugate of claim 1 in combination with a pharmaceutically acceptable carrier.

13. A pharmaceutical composition of claim 12 comprising a mixture of conjugates comprising saccharides from N. meningitidis serogroups A, C, W135 and Y.

14. The pharmaceutical composition of claim 13 , wherein the conjugates comprising saccharides from N. meningitidis serogroups A, C, W135 and Y are separate conjugates for each saccharide.

15. The pharmaceutical composition of claim 14 , wherein the conjugates comprising saccharides from N. meningitidis serogroups A, C, W135 and Y are based on the same carrier.

16. A pharmaceutical composition comprising a conjugate of claim 2 in combination with a pharmaceutically acceptable carrier.

17. A pharmaceutical composition of claim 16 comprising a mixture of conjugates comprising saccharides from N. meningitidis serogroups A, C, W135 and Y.

18. The pharmaceutical composition of claim 17 , wherein the conjugates comprising saccharides from N. meningitidis serogroups A, C, W135 and Y are separate conjugates for each saccharide.

19. The pharmaceutical composition of claim 18 , wherein the conjugates comprising saccharides from N. meningitidis serogroups A, C, W135 and Y are based on the same carrier.

20. A method for raising an immune response in a mammal, comprising administering a conjugate of claim 1 to the mammal.

21. A method for raising an immune response in a mammal, comprising administering a conjugate of claim 2 to the mammal.

22. A method for raising an immune response in a mammal, comprising administering a pharmaceutical composition of claim 16 to the mammal.

Assignees

• Novartis Ag
• Glaxosmithkline Biologicals Sa

Inventors

• Costantino Paolo
• Romano Maria Rosaria

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• C07K14/3156 Primary

  from Streptococcus pneumoniae (Pneumococcus) (Streptokinase C07K14/3153) · CPC title

• A61K39/0013

  Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine · CPC title

• A61K2039/6037

  Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title